Infectious Diseases

The Role of the Forensic Physician
  • Felicity Nicholson
Part of the Forensic Science and Medicine book series (FSM)


Infections have plagued doctors for centuries, in both the diagnosis of the specific diseases and the identification and subsequent management of the causative agents. There is a constant need for information as new organisms emerge, existing ones develop resistance to current drugs or vaccines, and changes in epidemiology and prevalence occur. In the 21st century, obtaining this information has never been more important. Population migration and the relatively low cost of flying means that unfamiliar infectious diseases may be brought into industrialized countries. An example of this was an outbreak of severe acute respiratory syndrome (SARS), which was first recognized in 2003. Despite modern technology and a huge input of money, it took months for the agent to be identified, a diagnostic test to be produced, and a strategy for disease reporting and isolation to be established. There is no doubt that other new and fascinating diseases will continue to emerge.


Herpes Zoster Severe Acute Respiratory Syndrome Severe Acute Respiratory Syndrome Intravenous Drug User Head Louse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    UK Health Guidelines. Guidance for Clinical Health Care Workers: Protection Against Infection with Blood-borne Viruses; Recommendations of the Expert Advisory Group on AIDS and the Advisory Group on Hepatitis. [HSC 1998/063], NHS Executive, London, UK, 1998.Google Scholar
  2. 2.
    Guidelines for Hand Hygiene in Health Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Mob. Mortal. Wkly. Rep. 51: 1–44, 2002.Google Scholar
  3. 3.
    National Model Regulations for the Control of Workplace Hazardous Substances. Commonwealth of Australia, National Occupational Health and Safety Committee. [NOHSC:1005], 1994.Google Scholar
  4. 4.
    Nicholson F. Chapter 4: Infectious diseases and an at risk exposure. In: Stark M. M., Rogers, D.J., Norfolk, G. A. eds., Good Practice Guidelines for Forensic Medical Examiners, 2nd Ed. Metropolitan Police. GPG Editors, Oxford, UK, 2004.Google Scholar
  5. 5.
    Bolyard, E, A., Tablan, O. C., Williams, W. W., Pearson, M. L., Shapiro, C. N., Deitchman, S. D., and the Hospital Infection Control Practices Advisory Committee. Guideline for infection control in health care personnel. Am. J. Infect. Control. 26:289–354, 1998.CrossRefGoogle Scholar
  6. 6.
    Prevalence of HIV and hepatitis infections in the United Kingdom 2000. Annual report of the Unlinked Anonymous Prevalence Monitoring Programme. Report from the Unlinked Anonymous Surveys Steering Group. Department of Health, London, UK, 2001.Google Scholar
  7. 7.
    A Strategy for Infectious Diseases-Progress Report. Blood-borne and sexually transmitted viruses: hepatitis. Department of Health, London, UK, 2002.Google Scholar
  8. 8.
    Perspectives in disease prevention and health promotion update. Universal precautions for prevention of transmission of human immuno-deficiency virus, hepatitis B virus and other bloodborne pathogens in health-care settings. Morb. Mortal. Wkly. Rep. 37:377–388, 1988.Google Scholar
  9. 9.
    Martinson, F. E., Weigle, K.A., Royce, R. A., Weber, D. J., Suchindran, C. M., Lemon, S. M. Risk factors for horizontal transmission of hepatitis B in a rural district in Ghana. Am. J. Epidemiol. 147:478–487, 1998.PubMedGoogle Scholar
  10. 10.
    Verma, G., Dalai, P., Bapat, M., Rathi, P., Abraham, P. Familial clustering of hepatitis B infection: study of a family. Indian J. Gastroenterol. 22:22–23, 2003.PubMedGoogle Scholar
  11. 11.
    Erol, S., Ozkurt, Z., Ertek, M., Tasyaran, M. A. Intrafamilial transmission of hepatitis B in the Eastern Anatolian region of Turkey. Euro. J. Gastroenterol. Hepatol. 15:345–349, 2003.CrossRefGoogle Scholar
  12. 12.
    Hutchinson, S., Goldberg, D., Gore, S. et al. Hepatitis B outbreak at Glenochil prison during January to June 1993. Epidemiol. Infect. 121:185–191,1998.PubMedCrossRefGoogle Scholar
  13. 13.
    European Network for HIV/AIDS and Hepatitis Prevention in Prisons. Second annual report. The Network, Bonn and Marseille, May 1998.Google Scholar
  14. 14.
    Weild, A. R., Gill, O. N., Bennett, D., Livingstone, S. J. M., Parry, J. V., Curran, L. Prevalence of HIV, hepatitis B and hepatitis C antibodies in prisoners in England and Wales; a national survey. Communicable Dis. Public Health. 3:121–126, 2000.Google Scholar
  15. 15.
    Alter, M. J. The epidemiology of acute and chronic hepatitis C. Clin. Liver Dis. 1:559–562, 1997.PubMedCrossRefGoogle Scholar
  16. 16.
    Frank, C., Mohamed, M. K., Strickland, G. T. The role of the parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 355:887–891, 2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Chronic Hepatitis C: Disease Management. NIH publication No. 03-4230. February 2003.Google Scholar
  18. 18.
    Hepatitis C strategy for England. Department of Health, London, UK, August 14, 2002.Google Scholar
  19. 19.
    Gish, R. G., Lau, J. Y. N. Hepatitis C virus: eight years old. Viral Hepatitis Rev. 3:17–37, 1997.Google Scholar
  20. 20.
    Ramsay, M. E., Balogun, M. A., Collins, M., Balraj, V. Laboratory surveillance of hepatitis C virus in England and Wales: 1992–1996. Communicable Dis. Public Health. 1:89–94, 1998.Google Scholar
  21. 21.
    Hepatitis D. Sean Lacey, Assistant Professor, Dept. of Medicine, Case Western Reserve University. http://www.emedicine@topic994.htm. Accessed Feb. 2004. Last update September 6, 2001.
  22. 22.
    Cumulative UK Data to end of December 2002. AIDS/HIV quarterly surveillance tables provided by the PHLS AIDS centre (CDSC) and the Scottish centre for Infection and Environmental Health. No 57: 02/4. February 2003.Google Scholar
  23. 23.
    HIV and AIDS in the UK in 2001. Communicable Disease Surveillance Centre. An update. November 2002.Google Scholar
  24. 24.
    International Perinatal HIV Group. Mode of vertical transmission of HIV-1. A metanalysis of fifteen prospective cohort studies. N. Engl. J. Med. 340:977–987, 1999.Google Scholar
  25. 25.
    Duong, T., Ades, A., Gibbs, D. M., et al. Vertical transmission rate for HIV in the British Isles estimated on Surveillance data. Br. Med. J. 319:1227–1229, 1999.Google Scholar
  26. 26.
    Limb, S., Kawar, M., Forster, G. E. HIV post-exposure prophylaxis after sexual assault: the experience of a sexual assault service in London. Int. J. STDS AIDS. 13:602–605, 2002.CrossRefGoogle Scholar
  27. 27.
    HIV Post-Exposure Prophylaxis: Guidance from the UK Chief Medical Officer’s Expert Advisory Group on AIDS. UK Health Department, London, UK, 2000.Google Scholar
  28. 28.
    Jochimsen, E. M. Failures of zidovudine post exposure prophylaxis. Am. J. Med. 102:52–55, 1997.PubMedCrossRefGoogle Scholar
  29. 29.
    Hawkins, D. A., Asboe, D., Barlow, K., Evans, B. Seroconversion to HIV-1 following a needlestick injury despite combination post-exposure prophylaxis. J. Infect. 43:12–15, 2001.PubMedGoogle Scholar
  30. 30.
    Salisbury, D. M., Begg, N. T. Department of Health, Immunisation Against Infectious Disease. United Kingdom: Her Majesty’s Stationery Office, London, UK, 1996.Google Scholar
  31. 31.
    Sinha, D. P. Chickenpox—disease predominantly affecting adults in rural West Bengal, India. Int. J. Epidemiol. 5:367–374, 1996.CrossRefGoogle Scholar
  32. 32.
    Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly. Rep. 45:1–36, 1996.Google Scholar
  33. 33.
    Fairley, C. K., Miller, E. Varicella-zoster virus epidemiology. A changing scene? J. Infect. Dis. 174(Suppl 3):314–319, 1996.Google Scholar
  34. 34.
    Smego, R. A., Asperilla, M. O. Use of Acyclovir for varicella pneumonia during pregnancy. Obstet. Gynecol. 78:1112–1116, 1991.PubMedGoogle Scholar
  35. 35.
    Pastuszak, A. L., Levy, M., Schick, B., et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N. Engl. J. Med. 330:901–905, 1994.PubMedCrossRefGoogle Scholar
  36. 36.
    Miller, E., Cradoc-Watson, J. E., Ridehalgh, M. K. Outcome in newborn babies given anti-varicella zoster immunoglobulin after perinatal maternal infection with varicella zoster virus. Lancet. 2:371–373, 1989.PubMedCrossRefGoogle Scholar
  37. 37.
    Gilden, D. H., Vafai, A., Shtram, Y., et al. Varicella-zoster virus DNA in human sensory ganglia. Nature. 306:478–80, 1983.PubMedCrossRefGoogle Scholar
  38. 38.
    Dworkin, R. H., Schmader, K. E. Epidemiology and natural history of herpes zoster and post herpetic neuralgia. In: Watson, C. P. N., Gershon, A. A., eds., Herpes Zoster and Postherpetic Neuralgia. 2nd Ed. Elsevier Press, New York, NY, 2001, pp. 39–64.Google Scholar
  39. 39.
    Desmond, R. A., Weiss, H. L., Arani, R. B., et al. Clinical applications for change-point analysis of herpes zoster pain. J. Pain Sys. Manage. 23:510–516, 2002.CrossRefGoogle Scholar
  40. 40.
    Gnann, J. W. Jr., Whitley, R. J. Herpes Zoster. N. Engl. J. Med. 347:340–346, 2002.PubMedCrossRefGoogle Scholar
  41. 41.
    Haustein, U. F., Hlawa, B. Treatment of scabies with permethrin versus lindane and benzoyl benzoate. Acta Derm. Venereol. (Stock). 69:348–351, 1989.Google Scholar
  42. 42.
    Brown, S., Becher, J., Brady, W. Treatment of ectoparasitic infections; review of the English-language literature. 1982–1992. Clin. Infect. Dis. 20(Suppl 1):S104–S109, 1995.PubMedGoogle Scholar
  43. 43.
    Klutymans, J., Van Belkum, A., Verbrugh, H. Nasal carriage of Staphylococcus aureus: epidemiology and control measures. Infect. Dis. Clin. North Am. 3:901–913, 1989.Google Scholar
  44. 44.
    Lowry, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339:520–532, 1998.CrossRefGoogle Scholar
  45. 45.
    Centers for Disease Control and Prevention. Community-acquired methicillin-resistant Staphylococcus aureus infections—Michigan. Morb. Mortal. Wkly. Rep. 30:185–187, 1981.Google Scholar
  46. 46.
    Saravolatz, L. D., Markowitz, N., Arking, L., Pohlod, D., Fisher, E. Methicillin-resistant Staphylococcus aureus, Epidmiologic observations during a community acquired outbreak. Ann. Intern. Med. 96:11–16, 1982.PubMedGoogle Scholar
  47. 47.
    Health Protection Agency. Emergence of PVL-producing strains of Staphylococcus aureus. Commun. Dis. Rep. CDR Wkly. [serial online]. 13: 2003. Available at Website: ( Accessed in Jan. 2004.
  48. 48.
    Summanen, P. H., Talan, D. A., Strong, C., et al. Bacteriology of skin and soft tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin. Infect. Dis. 20(Suppl 2):S279–S282, 1995.PubMedGoogle Scholar
  49. 49.
    Bohlen, L. M., Muhlemann, K., Dubuis, O., Aebi, C., Tauber, M. G. Outbreak among drug users caused by a clonal strain of group a streptococcus. Dispatches— emerging infectious diseases. Available at Website: ( Accessed March 2003.
  50. 50.
    Lettington, W. Bacteriological skin and subcutaneous infections in injecting drug users—relevance for custody. J. Clin. Forensic Med. 9:65–69, 2002.PubMedCrossRefGoogle Scholar
  51. 51.
    Passaro, D. J., Werner, S. B., McGee, J., MacKenzie, W. R., Vugia, D. J. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 279, 859–63, 1998.PubMedCrossRefGoogle Scholar
  52. 52.
    Brazier, J.S., Duerden, B. I., Hall, V., et al. Isolation and identification of clostridium spp from infections associated with injection of drugs: experiences of a microbiological investigation team. J. Med. Microbiol. 51: 985–989, 2002.PubMedGoogle Scholar
  53. 53.
    Greater Glasgow Health Board, SCIFH. Unexplained illness among drug injectors in Glasgow. Eurosurveillance 4: 500518, August 6, 2001.Google Scholar
  54. 54.
    Kuylaylat, M. N., Barakat, N., Stephan, R. N., Gutierrez, I. Embolization of illicit needle fragments. J. Emerg. Med. 11:403–408, 1993.CrossRefGoogle Scholar
  55. 55.
    Ngaage, D. L., Cowen, M. E. Right ventricular needle embolus in an injecting drug user: the need for early removal. Emerg. Med. J. 18:500–501, 2001.PubMedCrossRefGoogle Scholar
  56. 56.
    Spanierman, C. Departments of Emergency Medicine and Pediatrics, Lutheran General Hospital of Oak Brook, Advocate Health System. eMedicine-Human Bites, Available at Website: ( Accessed in Feb 2004.
  57. 57.
    Presutti, J. P. Prevention and treatment of dog bites. Am. Fam. Physician. 63:1567–1572, 2001.PubMedGoogle Scholar
  58. 58.
    Revis, D. R., Jr., Seagel, M. B. Human bites. Department of Plastic Surgery, University of Florida College of Medicine. eMedicine-Human Bites. Available at Website: ( Accessed in Feb 2004.
  59. 59.
    Guidelines for public health management of meningococcal diseases in the UK. Communicable Disease and Public Health. PHLS. 5:187–204, 2002.Google Scholar
  60. 60.
    Miller, E., Salisbury, D., Ramsay, M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 20(Suppl 1):S58–S67, 2001.PubMedCrossRefGoogle Scholar
  61. 61.
    Ramsay, M., Andrews, N., Kaczmarski, E., Miller, E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 357:195–196, 2001.PubMedCrossRefGoogle Scholar
  62. 62.
    PHLS. Quadrivalent meningoimmunisation required for pilgrims to Saudi Arabia. Commun. Dis. Rep. CDR Wkly. 11:8/11/2001. Accessed on May 11, 2004.
  63. 63.
    Boutet, R., Stuart, J. M., Kaczmarski, E., Gray, S. J., Jones, M., Andrews, N. Risk of laboratory-acquired meningococcal disease. J. Hosp. Infect. 49:282–284, 2001.PubMedCrossRefGoogle Scholar
  64. 64.
    Orr, H., Kaczmarski, E., Sarangi, J., Pankhania, B., Stuart, J. Cluster of meningococcal disease in rugby match spectators. Commun. Dis. Public Health. 4:316–317, 2001.PubMedGoogle Scholar
  65. 65.
    Salisbury, D. M., Begg, N. T. Immunisation against Infectious Disease. Her Majesty’s Stationery Office, London, UK, 1996.Google Scholar
  66. 66.
    CDSC. Ciprofloxacin as a chemoprophylactic agent for meningococcal disease— low risk of anaphylactoid reactions. Commun. Dis. Rep. Wkly. 11:2001.Google Scholar
  67. 67.
    Joint Formulary Committee 2002–03. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK, 2003.Google Scholar
  68. 68.
    Omerod, L. P., Watson, J. M., Pozniak, A., et al. Notification of tuberculosis an updated code of practice for England and Wales. J. Royal Coll. Phys. Lond. 31:299–303, 1997.Google Scholar
  69. 69.
    Statutory notifications to the Communicable Disease Surveillance Centre. Preliminary annual report on tuberculosis cases reported in England, Wales, and N. Ireland. Accessed in Dec. 2003.
  70. 70.
    The Interdepartmental Working Group on Tuberculosis. The prevention and control of tuberculosis in the United Kingdom: UK guidance on the prevention and control of transmission of 1. HIV-related tuberculosis 2. Drug-resistant, including multiple drug-resistant, tuberculosis. Department of Health, Scottish Office, The Welsh Office, Scotland, 1998.Google Scholar
  71. 71.
    Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax. 55:887–901, 2000.CrossRefGoogle Scholar
  72. 72.
    Cantwell, M. F., Snider, D. E., Cauthen, G. M., Onorato, I. M. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 272:535–539, 1994.PubMedCrossRefGoogle Scholar
  73. 73.
    Centers for Disease Control. Nosocomial transmission of multi-drug resistant tuberculosis among HIV-infected persons—Florida, New York, 1988–1991. Morb. Mortal. Wkly. Rep. 40:585–591, 1991.Google Scholar
  74. 74.
    Navin, T. R., McNabb, S. J. N., Crawford, J. T. The Continued Threat of Tuberculosis. Emerg. Infect. Dis. [serial online]. Available at Website:( Accessed November 2002.Google Scholar
  75. 75.
    Sepkowitz, D. V. Chapter 5: Tuberculosis in HIV-Infected Individuals. In: Lutwick, Larry I., ed., Tuberculosis—A Clinical Handbook. Chapman & Hall Medical, London, UK, 1995.Google Scholar
  76. 76.
    Murray, J. F. The White Plague: down and out, or up and coming? Am. Rev. Resp. Dis. 140:1788–1795.Google Scholar
  77. 77.
    Selwyn, P. A., Hartel, D., Lewis, V. A., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545–550, 1989.PubMedCrossRefGoogle Scholar
  78. 78.
    Wallis, R. S., Vjecha, M., Amir-Tahmasseb, M., et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated B2-microglobulin in HIV-1 associated tuberculosis. J. Infect. Dis. 167:43–48, 1993.PubMedGoogle Scholar
  79. 79.
    Long, R., Maycher, B., Scalcini, M., Manfreda, J. The chest roenterogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest. 99:123–127, 1991.PubMedCrossRefGoogle Scholar
  80. 80.
    Peiris, J. S. M., Lais, T., Poon, L. L. M., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 361:1319–1325, 2003.PubMedCrossRefGoogle Scholar
  81. 81.
    Donnelly, C. A., Ghani, A. C., Leung, G. M., et al. Epidemiological determinants of spread of causal agents of severe acute respiratory syndrome in Hong Kong. Lancet. 361:761–766, 2003.CrossRefGoogle Scholar
  82. 82.
    Alert, verification and public health management of SARS in post-outbreak period. World Health Organization. Available at Website: ( Accessed 14, 2003.
  83. 83.
    Gay, N. J., Morgan-Capner, P., Wright, J., Farrington, C. P., Miller, E. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol. Infect. 113:113–120, 1994.PubMedGoogle Scholar
  84. 84.
    Crowcroft, N. S., Walsh, B., Davison, K. L., Gungabissoon, U., PHLS Advisory Committee on Vaccination and Immunisation. Guidelines for the control of hepatitis A infection. Commun. Dis. Public Health. 4:213–227, 2001.PubMedGoogle Scholar
  85. 85.
    Irwin, D. J., Millership, S. Control of a community hepatitis A outbreak using hepatitis A vaccine. Commun. Dis. Public Health. 2:184–187, 1999.PubMedGoogle Scholar
  86. 86.
    Katz, M. H., Hsu, L., Wong, E., Liska, S., Anderson, L., Janssen, R. S. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. J. Infect. Dis. 175:1225–1229, 1997.PubMedGoogle Scholar
  87. 87.
    Harkess, J., Gildon, B., Istre, G. R. Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984–1987. Am. J. Public Health. 79:463–466, 1989.PubMedGoogle Scholar
  88. 88.
    Hutin, Y. J., Bell, B. P., Marshall, K. L., et al. Identifying target groups for a potential vaccination program during a hepatitis A community outbreak. Am. J. Public Health. 89:918–19, 1999.PubMedCrossRefGoogle Scholar
  89. 89.
    Hutin, Y. J., Sabin, K. M., Hutwagner, L. C., et al. Multiple modes of hepatitis A transmission among metamphetamine users. Am. J. Epidemiol. 152:186–192, 2000.PubMedCrossRefGoogle Scholar
  90. 90.
    Ochnio, J. J., Patrick, D., Hom, T. G., et al. Past infection with hepatitis A among Vancouver Street youth, injection drug users and men who have sex with men; implications for vaccination programmes. Can. Med. Assoc. J. 165:293–297, 2001.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Felicity Nicholson
    • 1
  1. 1.LondonUK

Personalised recommendations